55 filings
8-K
INBX
Inhibrx, Inc.
30 May 24
Termination of a Material Definitive Agreement
4:13pm
8-K
INBX
Inhibrx, Inc.
24 May 24
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
4:08pm
8-K
INBX
Inhibrx, Inc.
17 May 24
Other Events
5:29pm
8-K
INBX
Inhibrx, Inc.
9 May 24
Inhibrx Reports First Quarter 2024 Financial Results
4:08pm
8-K
INBX
Inhibrx, Inc.
8 May 24
Other Events
4:42pm
8-K
8jewd4 dgc
12 Mar 24
Other Events
4:02pm
8-K
xwh2i4vsvuc u9
28 Feb 24
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
9:12am
8-K
sof 165urc
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
8-K
3fe7yrtocesllhvp3
9 Nov 23
Inhibrx Reports Third Quarter 2023 Financial Results
4:03pm
8-K
xvx7cd3f9ej4 x5dro
2 Nov 23
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
9:16am
8-K
9ddatg z2g0wjbvh
19 Sep 23
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
4:03pm
8-K
zndhr1qq ximubcx9
29 Aug 23
Inhibrx Announces $200 Million Private Placement Financing
9:03am
8-K
3xg bkja8jujyi6l
7 Aug 23
Inhibrx Reports Second Quarter 2023 Financial Results
4:05pm
8-K
3u716o2ey0o6kfq
30 May 23
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
9:03am
8-K
ctwdf
25 May 23
Submission of Matters to a Vote of Security Holders
4:08pm
8-K
qm3upc2l
8 May 23
Inhibrx Reports First Quarter 2023 Financial Results
4:05pm
8-K
mok299qr
26 Apr 23
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials
9:01am
8-K
ey30sddij kanhi6
10 Mar 23
Regulation FD Disclosure
7:02pm
8-K
bxpwtk t8s7
6 Mar 23
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results
4:04pm
8-K
mb6hw kos0
16 Nov 22
Regulation FD Disclosure
9:01am